Rika Goda

NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel

Tsuyoshi Hamaguchi, Yasuhiro Matsumura, Masanobu Suzuki et al. · British Journal of Cancer · 2005 · 556 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

DETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTS

Rika Goda, Daichi Nagai, Kiyohiro Nishikawa et al. · Drug Metabolism and Disposition · 2006 · 56 citations

Medicine, Pharmacology, Toxicology +17

Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice

Yasushi Matsuzaki, Daichi Nagai, Eiji Ichimura et al. · Journal of Gastroenterology · 2006 · 37 citations

Medicine, Pharmacology, Toxicology +16

Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors

Hirofumi Mukai, Ken Kato, Taito Esaki et al. · Investigational New Drugs · 2016 · 33 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

An in vivo mechanism for the reduced peripheral neurotoxicity of NK105: a paclitaxel-incorporating polymeric micellar nanoparticle formulation

Iwao Nakamura, Eiji Ichimura, Rika Goda et al. · International Journal of Nanomedicine · 2017 · 28 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17